

Supplementary Table 1. Baseline Characteristics of Patients in AIC and Non-AIC Groups.

Characteristic	AIC (n = 20)	Non-AIC (n = 20)	P-value
Age (years)	64.85 ± 8.64	65.60 ± 8.93	0.788
Sex (Male/Female)	12/8	11/9	0.752
BMI (kg/m ²)	24.57 ± 3.64	23.93 ± 3.11	0.551
Maximum Tumor Diameter (cm)	4.0 (2.6, 5.9)	4.0 (3.0, 5.0)	0.596
Histological Differentiation, n (%)			0.337
Well/Moderately	13 (65 %)	10 (50 %)	
Poorly	7 (35 %)	10 (50 %)	
TNM Stage, n (%)			0.752
Stage I-II	11 (55 %)	10 (50 %)	
Stage III-IV	9 (45 %)	10 (50 %)	
Hypertension, n (%)	5 (25 %)	3 (15 %)	0.690*
Diabetes Mellitus, n (%)	2 (10 %)	1 (5 %)	0.999*

Abbreviations: BMI: Weight (kg) / Height (m)²; AIC: abdominal infectious complication.

Note: Data are presented as mean ±SD, n (%), or median (quartile). Normally distributed variables were used for the independent samples t-test, abnormally distributed variables were used for the Wilcoxon rank-sum test; χ^2 or Fisher test for categorical variables.

Fig.S1




Fig.S1. (A) Gating strategy for human MDSCs. Total MDSCs were defined as Lin⁻ HLA-DR⁻ CD11b⁺ CD33⁺ cells. (B) qPCR analysis of NOS2 and ARG1 in PBMCs from AIC and Non-AIC patients (n = 20 per group). (C) Gating strategy for mouse MDSCs. Total MDSCs were identified as CD11b⁺Gr-1⁺ cells within live single-cell populations. (D) qPCR analysis of MDSC-associated markers Nos2 and Arg1 in PBMCs from AIC and Non-AIC mice (n = 5 per group). Data are presented as mean ± SEM. **P* < 0.05, ***P* < 0.01, ****P* < 0.001, ns, not significant.

Fig.S2




Fig.S2. (A) Representative immunofluorescence images of NETs release from FACS-sorted MDSCs stimulated with recombinant IL-6 (25 ng/mL) in the presence or absence of Tocilizumab (145 ng/mL) for 24 hours. (B) Quantification of NETs stained for DNA (Hoechst) and MPO (n = 4 independent experiments). Data are presented as mean $\pm$ SEM. ** $P < 0.01$, *** $P < 0.001$; ns, not significant.

Western blots include the molecular mass markers

